Sodium Valproate in the Treatment of Cerebellar Disorders

Andreas N. Neophytides, Paul F. Teychenne, Ronald F. Pfeiffer, Donald B. Calne

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Because of the high concentrations of ɣ-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.

Original languageEnglish (US)
Pages (from-to)455-457
Number of pages3
JournalCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Issue number4
StatePublished - Nov 1979

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Sodium Valproate in the Treatment of Cerebellar Disorders'. Together they form a unique fingerprint.

Cite this